For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in ...

Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des ...

The Company received US FDA approval for the alfa pump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough ...

Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and ...

With its combination of expert care, affordable pricing, and the allure of a vibrant cultural experience, Mexico continues to ...

CrazyBulk has long been recognized as a leader in natural, legal performance supplements. In 2025, the brand has solidified ...

Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, MaxCyte is entitled to ...

Once issued, the allowed patent titled, “ Gut Microbiota-Activated PDE4 Inhibitor Prodrug ,” will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December ...

U.S. Patent No. 12,202,873 – Superagonists, Partial Agonists and Antagonists of IL-2. Also granted in Switzerland, China, Germany, France, United Kingdom, India, and Japan and allowed in Canada with ...

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on ...

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more ...